W
WAVEMAN · COMPANY
AKTS · Aktis Oncology, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

AKTS

Aktis Oncology, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0002035832
FORM 144 · 4☆ WATCH
INSIDER NET · 180D
-$3.0M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
82
13F, latest reported quarter
REVENUE GROWTH
+111.4%
XBRL, annual
NET MARGIN
-713.5%
CONVERSIONS · 180D
5
codes C/M, not in net · $433.6K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$3.0M over 180 days
-$3.0M over 90 days
below 73% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
82 funds added or opened last quarter
more than 58% of Pharma & Biotech
REVENUE
+111.4% year over year (latest quarter)
more than 86% of Pharma & Biotech
MARGIN
-713.5% net margin (latest quarter)
below 85% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
12.8 days to cover · settled 2026-07-31
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$3.0M across 3 people in 180 days.
82 funds added or opened positions in the latest 13F quarter, of 116 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +20.8%
+20.8%12M
-32%-7%+19%+44%2026-012026-022026-032026-052026-062026-072026-09 2026-01-12 · NODELMAN OLEG bought $37.4M2026-01-12 · MPM ONCOLOGY INNOVATIONS FUND LP bought $20.0M2026-01-12 · GADICKE ANSBERT bought $20.0M2026-01-12 · VIDA VENTURES II-A, LLC bought $14.6M2026-01-12 · Kim Helen Susan bought $14.6M2026-01-12 · Foley Todd bought $4.2M2026-01-12 · NODELMAN OLEG bought $2.6M2026-07-08 · Czibere Akos sold $861.7K2026-07-08 · Ron-Bigger Shulamit sold $838.1K2026-07-08 · Ron-Bigger Shulamit sold $428.7K2026-01-12 · VIDA VENTURES II-A, LLC bought $405.8K2026-01-12 · Kim Helen Susan bought $405.8K2026-07-08 · Czibere Akos sold $401.5K2026-07-08 · Czibere Akos sold $125.5K2026-07-08 · Ron-Bigger Shulamit sold $120.7K2026-07-20 · Herrmann Ken sold $86.1K2026-07-17 · Herrmann Ken sold $77.3K2026-07-20 · Herrmann Ken sold $33.2K2026-01-20 · EcoR1 Capital, LLC filed a 5%+ stake (9.1%)2026-01-20 · Oleg Nodelman filed a 5%+ stake (9.1%)2026-01-20 · EcoR1 Capital Fund Qualified, L.P. filed a 5%+ stake (8.2%)2026-01-20 · MPM BIOVENTURES 2018, L.P. filed a 5%+ stake (7.4%)2026-01-20 · MPM BIOVENTURES 2018 (B), L.P. filed a 5%+ stake (0.4%)2026-01-20 · MPM BioVentures 2018 GP LLC filed a 5%+ stake (7.8%)2026-01-20 · MPM ASSET MANAGEMENT INVESTORS BV2018 LLC filed a 5%+ stake (0.1%)2026-01-20 · MPM BioVentures 2018 LLC filed a 5%+ stake (7.9%)2026-01-20 · MPM ONCOLOGY INNOVATIONS FUND LP filed a 5%+ stake (1.6%)2026-01-20 · MPM Oncology Innovations Fund GP LLC filed a 5%+ stake (1.6%)2026-01-20 · Oncology Impact Private Investment Fund 2, L.P. filed a 5%+ stake (9.1%)2026-01-20 · MPM Oncology Investments 2 LLC filed a 5%+ stake (9.1%)2026-01-20 · MPM ASSET MANAGEMENT LLC filed a 5%+ stake (0.6%)2026-01-20 · ANSBERT GADICKE filed a 5%+ stake (19.3%)2026-01-20 · LUKE EVNIN filed a 5%+ stake (9.5%)2026-01-20 · Todd Foley filed a 5%+ stake (8.0%)2026-01-15 · Eli Lilly and Company filed a 5%+ stake (11.9%)2026-07-20 · KEN HERRMANN filed to sell $119.3K2026-07-17 · KEN HERRMANN filed to sell $77.3K2026-07-08 · SHULAMIT RON-BIGGER filed to sell $1.4M2026-07-08 · AKOS CZIBERE filed to sell $1.4M
INSIDER BUYINSIDER SELL13D/G STAKEFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $3.0M sold by insiders over 180 days, 82 funds added last quarter, $3.0M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Aktis Oncology, Inc. insiders sold a net $3.0M of stock across 66 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Herrmann Ken
Director
SELL
2026-07-20
3,506.0
$86.1K
Herrmann Ken
Director
SELL
2026-07-20
1,350.0
$33.2K
Herrmann Ken
Director
SELL
2026-07-17
3,065.0
$77.3K
Czibere Akos
Chief Medical Officer
SELL
2026-07-08
14,800.0
$401.5K
Czibere Akos
Chief Medical Officer
SELL
2026-07-08
30,829.0
$861.7K
66 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 61 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
MPM BIOIMPACT LLC
4,835,872.0 sh
$155.9M
EcoR1 Capital, LLC
4,824,469.0 sh
$155.5M
Blue Owl Capital Holdings LP
3,070,219.0 sh
$99.0M
BlackRock, Inc.
2,278,358.0 sh
$73.4M
WELLINGTON MANAGEMENT GROUP LLP
1,966,244.0 sh
$63.4M
5%+ owners
13D = intent to influence · 13G = passive
EcoR1 Capital, LLC
ACTIVIST 13D · 2026-01-20
9.1%
Oleg Nodelman
ACTIVIST 13D · 2026-01-20
9.1%
EcoR1 Capital Fund Qualified, L.P.
ACTIVIST 13D · 2026-01-20
8.2%
MPM BIOVENTURES 2018, L.P.
ACTIVIST 13D · 2026-01-20
7.4%
MPM BIOVENTURES 2018 (B), L.P.
ACTIVIST 13D · 2026-01-20
0.4%
Planned sales · Form 144
Filed before the sale — intent, not a trade
KEN HERRMANN
FILED 2026-07-20
$119.3K
KEN HERRMANN
FILED 2026-07-17
$77.3K
SHULAMIT RON-BIGGER
FILED 2026-07-08
$1.4M
AKOS CZIBERE
FILED 2026-07-08
$1.4M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Meridian Small Cap Growth Fund
$1.9M POSITION · AS OF 2026-03-31
0.8%
Eventide Healthcare & Life Sciences Fund
$9.1M POSITION · AS OF 2026-03-31
0.6%
HARTFORD HEALTHCARE HLS FUND
$260.0K POSITION · AS OF 2026-03-31
0.2%
T. Rowe Price Health Care ETF
$48.7K POSITION · AS OF 2026-03-31
0.2%
Select Biotechnology Portfolio
$7.7M POSITION · AS OF 2026-02-28
0.1%
T. Rowe Price Small-Cap Stock Fund, Inc.
$11.0M POSITION · AS OF 2026-03-31
0.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 2 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
2
Phase 1
2 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →